Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Undiscovered Gems In The US Featuring Anbio Biotechnology And 2 Other Small Caps

In This Article:

The United States market has remained flat over the past week but has shown a robust 21% increase over the last year, with earnings projected to grow by 14% annually. In this dynamic environment, identifying small-cap stocks like Anbio Biotechnology that possess strong growth potential and innovative capabilities can offer intriguing opportunities for investors seeking to uncover lesser-known gems.

Top 10 Undiscovered Gems With Strong Fundamentals In The United States

Name

Debt To Equity

Revenue Growth

Earnings Growth

Health Rating

Eagle Financial Services

125.65%

12.07%

2.64%

★★★★★★

Morris State Bancshares

9.72%

4.93%

6.51%

★★★★★★

Wilson Bank Holding

NA

7.87%

8.22%

★★★★★★

Omega Flex

NA

0.39%

2.57%

★★★★★★

Oakworth Capital

31.49%

14.78%

4.46%

★★★★★★

ASA Gold and Precious Metals

NA

7.47%

-26.86%

★★★★★★

Parker Drilling

46.05%

0.86%

52.25%

★★★★★★

Teekay

NA

-0.89%

62.53%

★★★★★★

Anbio Biotechnology

NA

8.43%

184.88%

★★★★★★

FRMO

0.08%

38.78%

45.85%

★★★★★☆

Click here to see the full list of 284 stocks from our US Undiscovered Gems With Strong Fundamentals screener.

Let's review some notable picks from our screened stocks.

Anbio Biotechnology

Simply Wall St Value Rating: ★★★★★★

Overview: Anbio Biotechnology specializes in providing in vitro diagnostics (IVD) products globally and has a market cap of $253.25 million.

Operations: Anbio Biotechnology generates revenue primarily from its Surgical & Medical Equipment segment, totaling $9.50 million.

Anbio Biotechnology, a nimble player in the biotech arena, has captured attention with its recent $8 million IPO and inclusion in the NASDAQ Composite Index. Over the past year, Anbio's earnings surged by 185%, outpacing industry growth of 37%. Despite being debt-free for five years and having high non-cash earnings, Anbio's shares remain highly illiquid. The company is making strides with innovative diagnostic solutions like its Dry Chemiluminescence Immunoassay (CLIA) Solution ADL-1000 and Point-of-Care Testing products showcased at Medlab Middle East 2025. These advancements position Anbio as a promising contender in rapid diagnostics.

NasdaqGM:NNNN Earnings and Revenue Growth as at Feb 2025
NasdaqGM:NNNN Earnings and Revenue Growth as at Feb 2025

DRDGOLD

Simply Wall St Value Rating: ★★★★★☆

Overview: DRDGOLD Limited is a gold mining company focused on extracting gold from the retreatment of surface mine tailings in South Africa, with a market capitalization of approximately $909.87 million.

Operations: DRDGOLD generates revenue primarily from its Ergo and FWGR operations, with Ergo contributing ZAR 5.05 billion and FWGR adding ZAR 2.02 billion. The company's financial performance is influenced by these segments, reflecting its focus on gold extraction from surface mine tailings in South Africa.